Education and Training
Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.
The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.
Stanford is currently not accepting patients for this trial.
Intervention(s):
- behavioral: Counseling
- behavioral: Self-help guide
- drug: Pharmacotherapy
- behavioral: Genetic feedback, verbal
- behavioral: Genetic feedback, printed
Eligibility
Inclusion and exclusion criteria are the same for participants in the formative interviews
(Study A) and the feasibility RCT (Study B) except that Study A will include African
American and European American smokers and Study B will include European American smokers.
Inclusion criteria:
- Adults (aged 18 or older)
- Currently smoke at least 10 cigarettes per day
- Motivated to quit smoking (>=5 on a 10-point Likert scale)
- Have a telephone
- Read and speak English.
Exclusion criteria:
- Any medical contraindications for transdermal nicotine replacement therapy (NRT) or
sustained-release bupropion hydrochloride (bupropion) use based on the package labels
(e.g., for bupropion, risk of seizure)
- DSM-IV Axis I diagnosis (other than nicotine dependence)
- Subjects who meet criteria for current major depression, or who demonstrate evidence
of suicidal ideation at screening will be referred to treatment for depression and
will be excluded from the study
- Must agree not to seek other treatment for smoking cessation during the study.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Sean David
6504984687
Not Recruiting